Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

作者：David E. Jones, Pol F. Boudes, Mark G. Swain, Christopher L. Bowlus, Michael R. Galambos, Bruce R. Bacon, Yvonne Döerffel, Norman Gitlin, Stuart C. Gordon, Joseph A. Odin, David A. Sheridan, M A Wörns, Virginia Clark, Linsey Corless, Heinz Hartmann, Mark E. Jonas, Andreas Emanuel Kremer, George F. Mells, Peter Buggisch, Bradley L. Freilich, Cynthia Levy, John Moore Vierling, David E. Bernstein, Marek Hartleb, Ewa Janczewska, Fedja A. Rochling, Hemant Shah, Mitchell L. Shiffman, John H. F. Smith, Yun‐Jung Choi, Alexandra S. Steinberg, Mónika Varga, Harinder Chera, Robert L. Martin, Charles A. McWherter, Gideon Morris Hirschfield · 发表于：˜The œLancet. Gastroenterology & hepatology · 年份：2017 · DOI：10.1016/s2468-1253(17)30246-7 · 被引用次数：191 · 研究领域：Liver Diseases and Immunity、Drug Transport and Resistance Mechanisms、Pediatric Hepatobiliary Diseases and Treatments